Back

Eli Lilly’s EloraTZP delivers up to 23.3% weight loss in 48 weeks

Verifying
  • Eli Lilly announced mid-stage trial results for its obesity drug EloraTZP.
  • 23.3% was the maximum weight loss recorded after 48 weeks.
  • EloraTZP outperformed Novo Nordisk’s tirzepatide alone in patients with type 2 diabetes.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.